C. Jehn, M. Pannenbeckers, A. Klapproth, Farouk Dahmash, H. Salwender, Anju Singh, Yana Shikova, J. Schlichting, S. Meyer, C. Niggemann, M. Vierbuchen, A. Elmaagacli
Induction therapy (IT) with anthracycline and cytarabine (DA) is, despite a new era with targeted therapies such as FLT-3- or IDH-1/2- inhibitors, still the backbone of treatment for acute myeloid leukemia (AML). In this retrospective study we investigated possible risk factors for induction failure (IF) in 109 AML-patients, who were consecutively treated between 2013 and 2018 at our institution. We evaluated all patients at diagnosis for CMV IgG-status, LDH-value, platelet count, blast count in bone marrow (BM), Sorror comorbidity score (range 0-6), age (>70 years), cytogenetic risk factors according to the ELN classification (favourable [n=15], intermediate [n=56], or high risk [n=38]), occurrence of biclonal AML detected by flow cytometry and extramedullary AML-manifestation. In 43 (39%) patients an IF was observed. 38 of these patients went on to received a salvage therapy with idarubicin and fludarabine (n=30) or directly to allotransplant (n=8), whereas 5 patients received only best supportive care. Only age >70-years (p=0.020, odds ratio [OR] 2.5), cytogenetic adverse risk classification (p=0.014; OR 3.21), Sorror comorbidity score of >2, (p=0.019, OR 2.72), and > 40% blasts in BM (p=0.004; OR 3.64), had influence on the occurrence of IF after DA. Patients with IF or adverse cytogenetics and without subsequent transplant had a worse prognosis (2-year OS for IF 19.4% + 16.8% versus 86.9% + 7.6%, p=0.0001). In multivariate analyses for OS only transplantation (HR 0.37; [95% CI 0.19-0.76], p=0.007) and blasts >40% in BM (HR 2.24, [95% CI 1.07 – 4.68], p= 0.032), but not IF were identified as independent risk factors.
{"title":"Risk factors for induction failure of standard chemotherapy with anthracycline and cytarabine in Acute Myeloid Leukemia Patients","authors":"C. Jehn, M. Pannenbeckers, A. Klapproth, Farouk Dahmash, H. Salwender, Anju Singh, Yana Shikova, J. Schlichting, S. Meyer, C. Niggemann, M. Vierbuchen, A. Elmaagacli","doi":"10.15761/JTS.1000365","DOIUrl":"https://doi.org/10.15761/JTS.1000365","url":null,"abstract":"Induction therapy (IT) with anthracycline and cytarabine (DA) is, despite a new era with targeted therapies such as FLT-3- or IDH-1/2- inhibitors, still the backbone of treatment for acute myeloid leukemia (AML). In this retrospective study we investigated possible risk factors for induction failure (IF) in 109 AML-patients, who were consecutively treated between 2013 and 2018 at our institution. We evaluated all patients at diagnosis for CMV IgG-status, LDH-value, platelet count, blast count in bone marrow (BM), Sorror comorbidity score (range 0-6), age (>70 years), cytogenetic risk factors according to the ELN classification (favourable [n=15], intermediate [n=56], or high risk [n=38]), occurrence of biclonal AML detected by flow cytometry and extramedullary AML-manifestation. In 43 (39%) patients an IF was observed. 38 of these patients went on to received a salvage therapy with idarubicin and fludarabine (n=30) or directly to allotransplant (n=8), whereas 5 patients received only best supportive care. Only age >70-years (p=0.020, odds ratio [OR] 2.5), cytogenetic adverse risk classification (p=0.014; OR 3.21), Sorror comorbidity score of >2, (p=0.019, OR 2.72), and > 40% blasts in BM (p=0.004; OR 3.64), had influence on the occurrence of IF after DA. Patients with IF or adverse cytogenetics and without subsequent transplant had a worse prognosis (2-year OS for IF 19.4% + 16.8% versus 86.9% + 7.6%, p=0.0001). In multivariate analyses for OS only transplantation (HR 0.37; [95% CI 0.19-0.76], p=0.007) and blasts >40% in BM (HR 2.24, [95% CI 1.07 – 4.68], p= 0.032), but not IF were identified as independent risk factors.","PeriodicalId":74000,"journal":{"name":"Journal of translational science","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67490674","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
The diagnosis of drug-induced pneumopathy remains a challenge for clinicians, particularly in oncology field in which many new drugs are more and more used and induce uncommon adverse events by targeting specific pathways. We report the case of a patient with ovarian cancer who developed a rapidly progressive and life-threatening pneumopathy after initiation of olaparib. High dose of corticosteroids rapidly (in 3 days) improved the symptoms, decreased the oxygen supply and led to normalization of lung imaging. Olaparib-induced pneumopathy is rarely reported in literature. We discuss about the role of Poly (ADP-Ribose) polymerase (PARP) enzyme in the lung homeostasis and highlight the importance of consider high-doses steroids when suspecting this specific drug-induced pneumopathy.
{"title":"A rare but life-threatening pneumopathy induced by Olaparib: From a clinical case to a review of literature","authors":"G. Grisay, C. Percy, J. Pierrard, E. Seront","doi":"10.15761/JTS.1000366","DOIUrl":"https://doi.org/10.15761/JTS.1000366","url":null,"abstract":"The diagnosis of drug-induced pneumopathy remains a challenge for clinicians, particularly in oncology field in which many new drugs are more and more used and induce uncommon adverse events by targeting specific pathways. We report the case of a patient with ovarian cancer who developed a rapidly progressive and life-threatening pneumopathy after initiation of olaparib. High dose of corticosteroids rapidly (in 3 days) improved the symptoms, decreased the oxygen supply and led to normalization of lung imaging. Olaparib-induced pneumopathy is rarely reported in literature. We discuss about the role of Poly (ADP-Ribose) polymerase (PARP) enzyme in the lung homeostasis and highlight the importance of consider high-doses steroids when suspecting this specific drug-induced pneumopathy.","PeriodicalId":74000,"journal":{"name":"Journal of translational science","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67490808","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Since their discovery, micro-RNAs (miRNA) have raised wide interest as potential biomarkers for a host of diseases. These short strands of RNA, which do not code for protein, play an important role in the regulation of protein expression, by their ability to bind to complementary sequences on specific mRNA and thus suppress its translation. Several miRNAs, which have been detected in blood or tissue homogenates, have been shown to correlate significantly with the presence of prostate cancer, or with the risk of developing a tumor at a later stage, or with the subsequent course of the disease in patients with an established cancer diagnosis [1]. However, published reports are often contradictory. Putative biomarkers that are based on a statistical correlation without an understanding of their biological origin may not necessarily reflect a direct connection with the underlying pathological process. RNA is produced inside cells, and in a solid tissue consisting of several cell types, individual miRNA sequences may be produced in certain cells and not in others, perhaps under particular conditions of cellular physiology. This aspect of miRNA-biology cannot be addressed by analysis of biological fluids or tissue homogenates, a simple fact which is all too often overlooked in current literature.
{"title":"Cellular origin of miR-21 and miR-145 in prostate cancer. A reappraisal of their putative function in carcinogenesis","authors":"Erik Nesje Wiik, J. Halgunset","doi":"10.15761/JTS.1000381","DOIUrl":"https://doi.org/10.15761/JTS.1000381","url":null,"abstract":"Since their discovery, micro-RNAs (miRNA) have raised wide interest as potential biomarkers for a host of diseases. These short strands of RNA, which do not code for protein, play an important role in the regulation of protein expression, by their ability to bind to complementary sequences on specific mRNA and thus suppress its translation. Several miRNAs, which have been detected in blood or tissue homogenates, have been shown to correlate significantly with the presence of prostate cancer, or with the risk of developing a tumor at a later stage, or with the subsequent course of the disease in patients with an established cancer diagnosis [1]. However, published reports are often contradictory. Putative biomarkers that are based on a statistical correlation without an understanding of their biological origin may not necessarily reflect a direct connection with the underlying pathological process. RNA is produced inside cells, and in a solid tissue consisting of several cell types, individual miRNA sequences may be produced in certain cells and not in others, perhaps under particular conditions of cellular physiology. This aspect of miRNA-biology cannot be addressed by analysis of biological fluids or tissue homogenates, a simple fact which is all too often overlooked in current literature.","PeriodicalId":74000,"journal":{"name":"Journal of translational science","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67491086","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Herwig R, Panhofer Tp, Greilberger M, Greilberger J
Aim: Coronavirus Disease (COVID-19) is caused by the newly emerged coronavirus SARS-CoV-2. To prevent further spread of SARS-CoV-2 and to provide a possible prophylaxis and treatment option we report about our experience on the application of two preparations with a clinical complete recovery of five patients, including two breastfed babies, from a Coronavirus disease with severe symptoms. Material and methods: Sedeprovid (ImmunoD ® CLS ℗ ) were applied twice a day and AlphaH ℗ 20 ml concentrate was consumed once a day in the morning. The course of disease and symptoms before, during and after treatment were recorded. Results: Prior to treatment, the patients suffered from severe symptoms of confirmed COVID-19 infections, including cough, inappetence, tiredness, bone and body pain, loss of taste and smell and body temperature of ≥39ºC for several days. Within 24 hours after application of ImmunoD ® CLS ℗ and AlphaH ℗ a significant reduction of symptoms and a drop down of maximal body temperature was recorded. A complete recovery with normal body temperature and normal or close to normal activity was documented after 48 hours. No side effects were reported from the patients or the parents. Conclusion: The combination of ImmunoD ® CLS ℗ and AlphaH ℗ might offer a good treatment regimen for COVID-19 infected patients with moderate and severe disease progression before entering or after leaving the ICU ward. In addition, this protocol might be used as a prophylactic therapy option for healthcare providers. We strongly recommend the instant confirmation of these results in a controlled randomized trial for a possible rapid benefit of COVID-19 infected patients.
{"title":"Sedeprovid, a novel vitamin D based substance, plus AlphaH℗ lead to complete recovery from COVID-19 within 48 hours after application in a 7-months old baby, a 1.5-year-old toddler and three further adults","authors":"Herwig R, Panhofer Tp, Greilberger M, Greilberger J","doi":"10.15761/JTS.1000385","DOIUrl":"https://doi.org/10.15761/JTS.1000385","url":null,"abstract":"Aim: Coronavirus Disease (COVID-19) is caused by the newly emerged coronavirus SARS-CoV-2. To prevent further spread of SARS-CoV-2 and to provide a possible prophylaxis and treatment option we report about our experience on the application of two preparations with a clinical complete recovery of five patients, including two breastfed babies, from a Coronavirus disease with severe symptoms. Material and methods: Sedeprovid (ImmunoD ® CLS ℗ ) were applied twice a day and AlphaH ℗ 20 ml concentrate was consumed once a day in the morning. The course of disease and symptoms before, during and after treatment were recorded. Results: Prior to treatment, the patients suffered from severe symptoms of confirmed COVID-19 infections, including cough, inappetence, tiredness, bone and body pain, loss of taste and smell and body temperature of ≥39ºC for several days. Within 24 hours after application of ImmunoD ® CLS ℗ and AlphaH ℗ a significant reduction of symptoms and a drop down of maximal body temperature was recorded. A complete recovery with normal body temperature and normal or close to normal activity was documented after 48 hours. No side effects were reported from the patients or the parents. Conclusion: The combination of ImmunoD ® CLS ℗ and AlphaH ℗ might offer a good treatment regimen for COVID-19 infected patients with moderate and severe disease progression before entering or after leaving the ICU ward. In addition, this protocol might be used as a prophylactic therapy option for healthcare providers. We strongly recommend the instant confirmation of these results in a controlled randomized trial for a possible rapid benefit of COVID-19 infected patients.","PeriodicalId":74000,"journal":{"name":"Journal of translational science","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67491312","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Received: October 25, 2020; Accepted: October 29, 2020; Published: November 02, 2020 After successfully controlling the first surge of infection and death brought on by the Sars-Cov 2 virus, there is currently no doubt about the worldwide occurrence of a second wave of COVID-19 disease. In Europe, several countries are reporting more daily Covid-19 cases than they did during the first wave in March, although the higher numbers may be due to more people being tested [1]; hospitals are currently overwhelmed.
{"title":"The half-life of truth in medicine regarding the Covid-19 disease","authors":"C. Bastid, J. Frossard","doi":"10.15761/jts.1000428","DOIUrl":"https://doi.org/10.15761/jts.1000428","url":null,"abstract":"Received: October 25, 2020; Accepted: October 29, 2020; Published: November 02, 2020 After successfully controlling the first surge of infection and death brought on by the Sars-Cov 2 virus, there is currently no doubt about the worldwide occurrence of a second wave of COVID-19 disease. In Europe, several countries are reporting more daily Covid-19 cases than they did during the first wave in March, although the higher numbers may be due to more people being tested [1]; hospitals are currently overwhelmed.","PeriodicalId":74000,"journal":{"name":"Journal of translational science","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67493036","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
S. Cacciapuoti, C. Marasca, M. Luciano, A. Masarà, M. Donnarumma, A. Balato, G. Fabbrocini
The mTORC1 protein complex consists of multiple components such as the serine/threonine kinase mTOR and the regulatoryassociated protein of mTOR (Raptor). Three highly researched upstream modulators of mTOR are the phosphatidylinositol 3-kinases (PI3Ks), protein kinase B (Akt). PI3K, and tumor necrosis factor alpha (TNFa) regulates Akt. Increased expression of PI3K, Akt, and TNFa amplifies mTORC1 activity as well (Figure 1) [3,4].
{"title":"mTOR in inflammatory skin diseases: Review of the literature and our experience","authors":"S. Cacciapuoti, C. Marasca, M. Luciano, A. Masarà, M. Donnarumma, A. Balato, G. Fabbrocini","doi":"10.15761/JTS.1000317","DOIUrl":"https://doi.org/10.15761/JTS.1000317","url":null,"abstract":"The mTORC1 protein complex consists of multiple components such as the serine/threonine kinase mTOR and the regulatoryassociated protein of mTOR (Raptor). Three highly researched upstream modulators of mTOR are the phosphatidylinositol 3-kinases (PI3Ks), protein kinase B (Akt). PI3K, and tumor necrosis factor alpha (TNFa) regulates Akt. Increased expression of PI3K, Akt, and TNFa amplifies mTORC1 activity as well (Figure 1) [3,4].","PeriodicalId":74000,"journal":{"name":"Journal of translational science","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67489458","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
N. M, Kuromatsu R, Niizeki T, Okamura S, Iwamoto H, Shimose S, Shirono T, Noda Y, Kamachi N, Koga H, Torimura T
Sorafenib is an oral multikinase inhibitor that has been approved to treat advanced hepatocellular carcinoma (HCC), although it is unclear whether the intrahepatic lesion is associated with prognosis of advanced HCC patients with extrahepatic metastasis treated with sorafenib. This study aimed to assess survival risk factors and evaluate therapeutic strategies for advanced HCC patients with extrahepatic metastasis treated with sorafenib. We analyzed the clinical data and treatment outcomes for 524 consecutive advanced HCC patients treated with sorafenib. Among them, 288 (55%) patients had extrahepatic metastasis. Among the patients with extrahepatic metastasis, 212 (74%) also had intrahepatic lesion. Multivariate analyses of overall survival identified intrahepatic lesion as an independent risk factor in patients with extrahepatic metastasis. Of those, 106 (50%) were treated with sorafenib monotherapy and 106 (50%) with alternatives to sorafenib treatment. The median survival time was 6.1 months for patients with sorafenib monotherapy and 11.6 months for those administered alternative treatments (p=0.0015). Our results indicated that sorafenib treatment may have negative long-term therapeutic effects in advanced HCC patients with extrahepatic metastasis and intrahepatic lesion, and that alternative treatments should be considered for these patients after sorafenib treatment.
{"title":"Evaluating the effect of intrahepatic lesion status on the prognosis of advanced hepatocellular carcinoma patients with extrahepatic metastasis: A prospective multicenter cohort study","authors":"N. M, Kuromatsu R, Niizeki T, Okamura S, Iwamoto H, Shimose S, Shirono T, Noda Y, Kamachi N, Koga H, Torimura T","doi":"10.15761/jts.1000368","DOIUrl":"https://doi.org/10.15761/jts.1000368","url":null,"abstract":"Sorafenib is an oral multikinase inhibitor that has been approved to treat advanced hepatocellular carcinoma (HCC), although it is unclear whether the intrahepatic lesion is associated with prognosis of advanced HCC patients with extrahepatic metastasis treated with sorafenib. This study aimed to assess survival risk factors and evaluate therapeutic strategies for advanced HCC patients with extrahepatic metastasis treated with sorafenib. We analyzed the clinical data and treatment outcomes for 524 consecutive advanced HCC patients treated with sorafenib. Among them, 288 (55%) patients had extrahepatic metastasis. Among the patients with extrahepatic metastasis, 212 (74%) also had intrahepatic lesion. Multivariate analyses of overall survival identified intrahepatic lesion as an independent risk factor in patients with extrahepatic metastasis. Of those, 106 (50%) were treated with sorafenib monotherapy and 106 (50%) with alternatives to sorafenib treatment. The median survival time was 6.1 months for patients with sorafenib monotherapy and 11.6 months for those administered alternative treatments (p=0.0015). Our results indicated that sorafenib treatment may have negative long-term therapeutic effects in advanced HCC patients with extrahepatic metastasis and intrahepatic lesion, and that alternative treatments should be considered for these patients after sorafenib treatment.","PeriodicalId":74000,"journal":{"name":"Journal of translational science","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67490869","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Karol De Aguiar-Quevedo, A. R. Sauri, J. Navarro, C. J. Aragón, J. C. Mojarrieta, N. Franch, M. Martínez, Encarnación Martínez Pérez, F. V. Sempere, J. C. P. Cuesta
Purpose: This work was designed to correlate the expression of markers of tumoral angiogenesis in lung adenocarcinoma as a prognostic factor and create a predictive model with these factors. Patients and methods: A clinical, observational and analytical research study was undertaken. This work sought to describe and compare prognosis value of angiogenic markers of 119 resected patients, classified as pathological stage IA. The tumour angiogenesis analysis was performed, the survival and predictive value of microvascular density (MVD) expression with tumoral relapse and survival were evaluated. Finally, an accurate score, “Angioscore”, was calculated by combining different markers. Results: Low MVD-CD34 is associated with a worse disease-free survival (DFS) and cancer specific survival (CSS). High MVD-CD31 is significantly related to reduce DFS and CSS. High MVC-CD105 is associated with worse clinical outcomes. The predictive capacity of these angiogenic markers independently it is not exact. The “Angioscore” is able to provide better information about patient prognosis (74.8% and 73.7%). Two groups were obtained with the risk value obtained by “Angioscore”. A significant difference in the prognosis of both groups was accomplished (p < 0.001). Being in the multivariate analysis the only independent prognostic factor in patients with lung ADC in stage IA of this series. Conclusion: Tumour angiogenesis is a prognostic factor in early stage lung adenocarcinoma, the analysis of this factor being more accurate using a score, with great predictive value
{"title":"Angiogenesis as a prognostic factor of pathological stage IA lung adenocarcinoma: developing an angiogenic score","authors":"Karol De Aguiar-Quevedo, A. R. Sauri, J. Navarro, C. J. Aragón, J. C. Mojarrieta, N. Franch, M. Martínez, Encarnación Martínez Pérez, F. V. Sempere, J. C. P. Cuesta","doi":"10.15761/JTS.1000382","DOIUrl":"https://doi.org/10.15761/JTS.1000382","url":null,"abstract":"Purpose: This work was designed to correlate the expression of markers of tumoral angiogenesis in lung adenocarcinoma as a prognostic factor and create a predictive model with these factors. Patients and methods: A clinical, observational and analytical research study was undertaken. This work sought to describe and compare prognosis value of angiogenic markers of 119 resected patients, classified as pathological stage IA. The tumour angiogenesis analysis was performed, the survival and predictive value of microvascular density (MVD) expression with tumoral relapse and survival were evaluated. Finally, an accurate score, “Angioscore”, was calculated by combining different markers. Results: Low MVD-CD34 is associated with a worse disease-free survival (DFS) and cancer specific survival (CSS). High MVD-CD31 is significantly related to reduce DFS and CSS. High MVC-CD105 is associated with worse clinical outcomes. The predictive capacity of these angiogenic markers independently it is not exact. The “Angioscore” is able to provide better information about patient prognosis (74.8% and 73.7%). Two groups were obtained with the risk value obtained by “Angioscore”. A significant difference in the prognosis of both groups was accomplished (p < 0.001). Being in the multivariate analysis the only independent prognostic factor in patients with lung ADC in stage IA of this series. Conclusion: Tumour angiogenesis is a prognostic factor in early stage lung adenocarcinoma, the analysis of this factor being more accurate using a score, with great predictive value","PeriodicalId":74000,"journal":{"name":"Journal of translational science","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67491156","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
The spectrum of cell surface proteins (the surfaceome) is one of the key focus of the drug industry, as 66% of approved human drugs registered in the Drug Bank database target a protein on the cell-surface, which makes the surfaceome of great therapeutical significance [1]. However, the comprehensive evaluation of the human surface protein repertoire remains a major challenge and several methods are needed to interrogate cell-surface proteins, in particular where low numbers of cells are available. The combination of gene expression analysis by next generation deep sequencing of bulk RNA-sequencing and single cell RNA-sequencing, integrated with cell-surface protein expression by proteomics, could potentially overcome inaccurate predictions of human cell-surface genes. This approach could avoid relying on an assumed correlation between mRNA levels and effective protein expression and define the cell proteome, including those proteins that are located on the cell surface. The for characterization in could constitute a for to in could be in and
{"title":"The power of surfaceome analysis in cancer to design novel targeted therapies","authors":"E. Marinari, D. Migliorini","doi":"10.15761/JTS.1000383","DOIUrl":"https://doi.org/10.15761/JTS.1000383","url":null,"abstract":"The spectrum of cell surface proteins (the surfaceome) is one of the key focus of the drug industry, as 66% of approved human drugs registered in the Drug Bank database target a protein on the cell-surface, which makes the surfaceome of great therapeutical significance [1]. However, the comprehensive evaluation of the human surface protein repertoire remains a major challenge and several methods are needed to interrogate cell-surface proteins, in particular where low numbers of cells are available. The combination of gene expression analysis by next generation deep sequencing of bulk RNA-sequencing and single cell RNA-sequencing, integrated with cell-surface protein expression by proteomics, could potentially overcome inaccurate predictions of human cell-surface genes. This approach could avoid relying on an assumed correlation between mRNA levels and effective protein expression and define the cell proteome, including those proteins that are located on the cell surface. The for characterization in could constitute a for to in could be in and","PeriodicalId":74000,"journal":{"name":"Journal of translational science","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67491248","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
G. Hagleitner, P. Pichler, P. Kiblböck, F. Fellner
present Abstract Cinematic rendering (CR) of cross-sectional imaging data is a novel technique of post-processing cross-sectional imaing data. Through photorealistic CR images it is now possible to deliver a better understanding anatomy and pathoanatomy for medical professionals, students and the general public alike. Computed tomography (CT) plays an essential role in diagnosis of abdominal aortic aneurysms (AAA), planning and follow-up in fenestrated endovascular aortic repair (FEVAR). In the last few years FEVAR has emerged as a standard procedure for the treatment of AAAs involving the visceral and renal arteries. In this article, we want to discuss the possible applications for CR images in a case with AAA treated with FEVAR.
{"title":"Cinematic rendering in vascular imaging: Abdominal aortic aneurysm (AAA) treated with fenestrated endovascular aortic repair (FEVAR)","authors":"G. Hagleitner, P. Pichler, P. Kiblböck, F. Fellner","doi":"10.15761/jts.1000427","DOIUrl":"https://doi.org/10.15761/jts.1000427","url":null,"abstract":"present Abstract Cinematic rendering (CR) of cross-sectional imaging data is a novel technique of post-processing cross-sectional imaing data. Through photorealistic CR images it is now possible to deliver a better understanding anatomy and pathoanatomy for medical professionals, students and the general public alike. Computed tomography (CT) plays an essential role in diagnosis of abdominal aortic aneurysms (AAA), planning and follow-up in fenestrated endovascular aortic repair (FEVAR). In the last few years FEVAR has emerged as a standard procedure for the treatment of AAAs involving the visceral and renal arteries. In this article, we want to discuss the possible applications for CR images in a case with AAA treated with FEVAR.","PeriodicalId":74000,"journal":{"name":"Journal of translational science","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67492961","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：